Cargando…

Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor

Lung adenocarcinoma (LADC) is the most prevalent lung cancer sub-type, and targeted therapy developed in recent years has made progress in its treatment. Erdafitinib, a potent and selective pan-FGFR tyrosine kinase inhibitor, has been confirmed to be effective for the treatment of LADC; however, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Xinmin, Zhu, Xue, Ji, Jiali, Zhong, Hongqin, Li, Xiyue, Zhao, Hongqing, Xie, Guijuan, Wang, Ke, Shu, Hong, Wang, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573074/
https://www.ncbi.nlm.nih.gov/pubmed/36235266
http://dx.doi.org/10.3390/molecules27196733
_version_ 1784810776642453504
author Meng, Xinmin
Zhu, Xue
Ji, Jiali
Zhong, Hongqin
Li, Xiyue
Zhao, Hongqing
Xie, Guijuan
Wang, Ke
Shu, Hong
Wang, Xun
author_facet Meng, Xinmin
Zhu, Xue
Ji, Jiali
Zhong, Hongqin
Li, Xiyue
Zhao, Hongqing
Xie, Guijuan
Wang, Ke
Shu, Hong
Wang, Xun
author_sort Meng, Xinmin
collection PubMed
description Lung adenocarcinoma (LADC) is the most prevalent lung cancer sub-type, and targeted therapy developed in recent years has made progress in its treatment. Erdafitinib, a potent and selective pan-FGFR tyrosine kinase inhibitor, has been confirmed to be effective for the treatment of LADC; however, the molecular mechanism responsible for this effect is unclear. The in vitro study showed that erdafitinib exhibited an outstanding anti-cancer activity in human LADC cell line A549 by inducing S-phase cell-cycle arrest and cell apoptosis. The mechanistic study based on the transcriptomic data revealed that erdafitinib exerted its anti-cancer effect by affecting the cell cycle-related pathway, and CDK2 was the regulatory target of this drug. In addition, CDK2 overexpression significantly attenuated the anti-cancer effect of erdafitinib by affecting the transcriptional activity and expression of E2F1, as well as the expression of CDK1. The in vivo study showed that erdafitinib presented an obvious anti-cancer effect in the A549 xenograft mice model, which was accompanied by the reduced expression of CDK2. Thus, this study demonstrates the anti-cancer effect of erdafitinib against LADC for the first time based on in vitro and in vivo models, whose activity is achieved by targeting CDK2 and regulating downstream E2F1-CDK1 signaling. This study may be helpful for expanding the clinical application of erdafitinib in treating LADC.
format Online
Article
Text
id pubmed-9573074
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95730742022-10-17 Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor Meng, Xinmin Zhu, Xue Ji, Jiali Zhong, Hongqin Li, Xiyue Zhao, Hongqing Xie, Guijuan Wang, Ke Shu, Hong Wang, Xun Molecules Article Lung adenocarcinoma (LADC) is the most prevalent lung cancer sub-type, and targeted therapy developed in recent years has made progress in its treatment. Erdafitinib, a potent and selective pan-FGFR tyrosine kinase inhibitor, has been confirmed to be effective for the treatment of LADC; however, the molecular mechanism responsible for this effect is unclear. The in vitro study showed that erdafitinib exhibited an outstanding anti-cancer activity in human LADC cell line A549 by inducing S-phase cell-cycle arrest and cell apoptosis. The mechanistic study based on the transcriptomic data revealed that erdafitinib exerted its anti-cancer effect by affecting the cell cycle-related pathway, and CDK2 was the regulatory target of this drug. In addition, CDK2 overexpression significantly attenuated the anti-cancer effect of erdafitinib by affecting the transcriptional activity and expression of E2F1, as well as the expression of CDK1. The in vivo study showed that erdafitinib presented an obvious anti-cancer effect in the A549 xenograft mice model, which was accompanied by the reduced expression of CDK2. Thus, this study demonstrates the anti-cancer effect of erdafitinib against LADC for the first time based on in vitro and in vivo models, whose activity is achieved by targeting CDK2 and regulating downstream E2F1-CDK1 signaling. This study may be helpful for expanding the clinical application of erdafitinib in treating LADC. MDPI 2022-10-09 /pmc/articles/PMC9573074/ /pubmed/36235266 http://dx.doi.org/10.3390/molecules27196733 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Meng, Xinmin
Zhu, Xue
Ji, Jiali
Zhong, Hongqin
Li, Xiyue
Zhao, Hongqing
Xie, Guijuan
Wang, Ke
Shu, Hong
Wang, Xun
Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
title Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
title_full Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
title_fullStr Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
title_full_unstemmed Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
title_short Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
title_sort erdafitinib inhibits tumorigenesis of human lung adenocarcinoma a549 by inducing s-phase cell-cycle arrest as a cdk2 inhibitor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573074/
https://www.ncbi.nlm.nih.gov/pubmed/36235266
http://dx.doi.org/10.3390/molecules27196733
work_keys_str_mv AT mengxinmin erdafitinibinhibitstumorigenesisofhumanlungadenocarcinomaa549byinducingsphasecellcyclearrestasacdk2inhibitor
AT zhuxue erdafitinibinhibitstumorigenesisofhumanlungadenocarcinomaa549byinducingsphasecellcyclearrestasacdk2inhibitor
AT jijiali erdafitinibinhibitstumorigenesisofhumanlungadenocarcinomaa549byinducingsphasecellcyclearrestasacdk2inhibitor
AT zhonghongqin erdafitinibinhibitstumorigenesisofhumanlungadenocarcinomaa549byinducingsphasecellcyclearrestasacdk2inhibitor
AT lixiyue erdafitinibinhibitstumorigenesisofhumanlungadenocarcinomaa549byinducingsphasecellcyclearrestasacdk2inhibitor
AT zhaohongqing erdafitinibinhibitstumorigenesisofhumanlungadenocarcinomaa549byinducingsphasecellcyclearrestasacdk2inhibitor
AT xieguijuan erdafitinibinhibitstumorigenesisofhumanlungadenocarcinomaa549byinducingsphasecellcyclearrestasacdk2inhibitor
AT wangke erdafitinibinhibitstumorigenesisofhumanlungadenocarcinomaa549byinducingsphasecellcyclearrestasacdk2inhibitor
AT shuhong erdafitinibinhibitstumorigenesisofhumanlungadenocarcinomaa549byinducingsphasecellcyclearrestasacdk2inhibitor
AT wangxun erdafitinibinhibitstumorigenesisofhumanlungadenocarcinomaa549byinducingsphasecellcyclearrestasacdk2inhibitor